Neogen Q3 revenue falls 4.4% to $211.2 million; raises FY26 revenue outlook
Neogen reported fiscal third-quarter 2026 revenue of $211.2 million, down 4.4% from a year earlier, and a net loss of $17.0 million, or $(0.08) per share, compared with a $10.9 million loss a year earlier. The company raised its fiscal 2026 revenue guidance to $857 million to $860 million, kept Adjusted EBITDA guidance at about $175 million, and announced a $160.0 million sale of its Genomics business to Zoetis.
Key points
- Q3 revenue was $211.2 million, down from $221.0 million; Animal Safety revenue fell 20.1% on third-party supplier issues
- Net loss was $17.0 million, or $(0.08) per diluted share; Adjusted EPS was $0.09 versus $0.10 a year earlier
- FY26 revenue guidance raised to $857 million to $860 million from $845 million to $855 million; Adjusted EBITDA guidance held at about $175 million
- Genomics business to be sold to Zoetis Inc. for $160.0 million, expected to close by the end of fiscal 2Q27
The filing
Written by AI on Nov 8, 2026, 6:56 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on April 09, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.